Acorda Therapeutics, Inc. (ACOR) Shares Sold by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. reduced its position in shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 15.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 328,163 shares of the biopharmaceutical company’s stock after selling 59,505 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.71% of Acorda Therapeutics worth $6,465,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System grew its holdings in Acorda Therapeutics by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 19,000 shares of the biopharmaceutical company’s stock worth $374,000 after acquiring an additional 100 shares during the period. Aperio Group LLC grew its holdings in Acorda Therapeutics by 2.7% during the second quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 343 shares during the period. Municipal Employees Retirement System of Michigan grew its holdings in Acorda Therapeutics by 3.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 410 shares during the period. Texas Permanent School Fund grew its holdings in Acorda Therapeutics by 1.4% during the second quarter. Texas Permanent School Fund now owns 34,066 shares of the biopharmaceutical company’s stock worth $671,000 after acquiring an additional 466 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in Acorda Therapeutics by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 41,040 shares of the biopharmaceutical company’s stock worth $862,000 after acquiring an additional 485 shares during the period.

Acorda Therapeutics, Inc. (ACOR) opened at 25.05 on Tuesday. The company has a 50 day moving average price of $23.38 and a 200-day moving average price of $19.79. The firm’s market cap is $1.17 billion. Acorda Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.16. The company had revenue of $139.40 million during the quarter, compared to the consensus estimate of $139.81 million. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.07 earnings per share. Equities research analysts anticipate that Acorda Therapeutics, Inc. will post $1.71 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Acorda Therapeutics, Inc. (ACOR) Shares Sold by Schwab Charles Investment Management Inc.” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://ledgergazette.com/2017/10/10/acorda-therapeutics-inc-acor-shares-sold-by-schwab-charles-investment-management-inc.html.

In related news, Director Lorin Randall sold 10,000 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $21.66, for a total value of $216,600.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $216,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Scopia Capital Management Lp acquired 766,201 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was bought at an average price of $19.23 per share, with a total value of $14,734,045.23. The disclosure for this purchase can be found here. Corporate insiders own 7.90% of the company’s stock.

ACOR has been the topic of a number of research analyst reports. BidaskClub raised Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, July 7th. Jefferies Group LLC initiated coverage on Acorda Therapeutics in a report on Monday, July 10th. They set a “hold” rating and a $22.00 target price on the stock. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 19th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Acorda T

A number of other large investors have also recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System grew its holdings in Acorda Therapeutics by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 19,000 shares of the biopharmaceutical company’s stock worth $374,000 after acquiring an additional 100 shares during the period. Aperio Group LLC grew its holdings in Acorda Therapeutics by 2.7% during the second quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 343 shares during the period. Municipal Employees Retirement System of Michigan grew its holdings in Acorda Therapeutics by 3.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 410 shares during the period. Texas Permanent School Fund grew its holdings in Acorda Therapeutics by 1.4% during the second quarter. Texas Permanent School Fund now owns 34,066 shares of the biopharmaceutical company’s stock worth $671,000 after acquiring an additional 466 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in Acorda Therapeutics by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 41,040 shares of the biopharmaceutical company’s stock worth $862,000 after acquiring an additional 485 shares during the period.

Acorda Therapeutics, Inc. (ACOR) opened at 25.05 on Tuesday. The company has a 50 day moving average price of $23.38 and a 200-day moving average price of $19.79. The firm’s market cap is $1.17 billion. Acorda Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.16. The company had revenue of $139.40 million during the quarter, compared to the consensus estimate of $139.81 million. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.07 earnings per share. Equities research analysts anticipate that Acorda Therapeutics, Inc. will post $1.71 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Acorda Therapeutics, Inc. (ACOR) Shares Sold by Schwab Charles Investment Management Inc.” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://ledgergazette.com/2017/10/10/acorda-therapeutics-inc-acor-shares-sold-by-schwab-charles-investment-management-inc.html.

In related news, Director Lorin Randall sold 10,000 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $21.66, for a total value of $216,600.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $216,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Scopia Capital Management Lp acquired 766,201 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was bought at an average price of $19.23 per share, with a total value of $14,734,045.23. The disclosure for this purchase can be found here. Corporate insiders own 7.90% of the company’s stock.

ACOR has been the topic of a number of research analyst reports. BidaskClub raised Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, July 7th. Jefferies Group LLC initiated coverage on Acorda Therapeutics in a report on Monday, July 10th. They set a “hold” rating and a $22.00 target price on the stock. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 19th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Acorda Therapeutics in a report on Friday, July 28th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $18.00 target price on shares of Acorda Therapeutics in a report on Tuesday, August 29th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $24.06.

Acorda Therapeutics Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply